0001193125-21-259324.txt : 20210827 0001193125-21-259324.hdr.sgml : 20210827 20210827160136 ACCESSION NUMBER: 0001193125-21-259324 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210825 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20210827 DATE AS OF CHANGE: 20210827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 211218849 BUSINESS ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 8-K 1 d179231d8k.htm 8-K 8-K
DE false 0001624658 0001624658 2021-08-25 2021-08-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 27, 2021 (August 25, 2021)

 

 

Allena Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   001-38268   45-2729920

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

One Newton Executive Park, Suite 202

Newton, Massachusetts

   02462
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (617) 467-4577

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   ALNA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 25, 2021, Allena Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between July 14, 2021 through August 24, 2021, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter does not result in the immediate delisting of the Company’s common stock from The Nasdaq Global Select Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until February 21, 2022 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day period, the closing bid price for the Company’s common stock closes at $1.00 or more per share for a minimum of 10 consecutive business days, as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Minimum Bid Price Requirement and the common stock will continue to be eligible for listing on The Nasdaq Global Select Market.

If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to transfer to The Nasdaq Capital Market and meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice to Nasdaq of its intention to cure the deficiency during the additional compliance period.

If it appears to the Staff that the Company will not be able to cure the deficiency, the Staff will provide written notice to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel (the “Panel”). The Company expects that its stock would remain listed pending the Panel’s decision. There can be no assurance that, if the Company does appeal the Staff’s delisting determination to the Panel, such appeal would be successful.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, secure a second period of 180 days to regain compliance, or maintain compliance with any of the other Nasdaq continued listing requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 27, 2021     Allena Pharmaceuticals, Inc.
    By:  

/s/ Richard Katz

  
      Richard D. Katz, M.D.  
      Chief Financial Officer  
EX-101.SCH 2 alna-20210825.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 alna-20210825_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 alna-20210825_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d179231d8k_htm.xml IDEA: XBRL DOCUMENT 0001624658 2021-08-25 2021-08-25 DE false 0001624658 8-K 2021-08-25 Allena Pharmaceuticals, Inc. 001-38268 45-2729920 One Newton Executive Park Suite 202 Newton MA 02462 (617) 467-4577 false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 25, 2021
Cover [Abstract]  
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0001624658
Document Type 8-K
Document Period End Date Aug. 25, 2021
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity File Number 001-38268
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One One Newton Executive Park
Entity Address, Address Line Two Suite 202
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02462
City Area Code (617)
Local Phone Number 467-4577
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d179231d8k.htm alna-20210825.xsd alna-20210825_lab.xml alna-20210825_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d179231d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d179231d8k.htm" ] }, "labelLink": { "local": [ "alna-20210825_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "alna-20210825_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "alna-20210825.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20210825", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d179231d8k.htm", "contextRef": "duration_2021-08-25_to_2021-08-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d179231d8k.htm", "contextRef": "duration_2021-08-25_to_2021-08-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allenapharma.com//20210825/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-21-259324-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-259324-xbrl.zip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end